PHOTO
People wait in line to have swab samples taken for the coronavirus disease (COVID-19) at a testing center in the Far Rockaway section of the Queens borough of New York, U.S., October 6, 2020.
Abbott Laboratories said on Wednesday its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study.
The results confirm the data submitted to the U.S. Food and Drug Administration in March for emergency use authorization, the medical device maker said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta) ((manojna.kalyani@thomsonreuters.com; +91 8061822700))
